Immunovant 

Yahoo Finance • 10 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Thursday afternoon with the NYSE Health Care Index dropping 0.6% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 10 days ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index down 0.6% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 10 days ago

Stocks Sink as President Trump Signals Iran War Will Drag On

The S&P 500 Index ($SPX) (SPY) today is down -1.13%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.15%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.53%.  June E-mini S&P futures (ESM26) are down -1.07%, and June E-mini Na... Full story

Yahoo Finance • 10 days ago

Immunovant falls on late-stage trial setback for TED therapy

[Stethoscope with the word Thyroid Disorders.] Fauzi Muda/iStock via Getty Images Immunovant (IMVT [https://seekingalpha.com/symbol/IMVT]) shares lost ~10% in the premarket on Thursday after the company, a subsidiary of Roivant Sciences (... Full story

Yahoo Finance • 10 days ago

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of proptosis improvement fr... Full story

Yahoo Finance • 28 days ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story

Yahoo Finance • last month

Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know

On February 17, 2026, Alpine Global Management disclosed a buy of 2,392,026 shares of Archer Aviation(NYSE:ACHR), with an estimated transaction value of $22.51 million based on quarterly average pricing. What happened According to a Febr... Full story

Yahoo Finance • last month

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

On February 17, 2026, Alpine Global Management disclosed a sale of 127,039 shares of Immunovant(NASDAQ:IMVT), with an estimated transaction value of $2.83 million based on quarterly average pricing. What happened According to a filing wi... Full story

Yahoo Finance • last month

Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares

On February 17, 2026, Alpine Global Management disclosed selling 783,379 shares of Trump Media & Technology Group(NASDAQ:DJT), an estimated $10.69 million trade based on quarterly average pricing. What happened According to a U.S. Securi... Full story

Yahoo Finance • 2 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous l... Full story

Yahoo Finance • 4 months ago

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?

Key Points Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share. The trade increased direct holdings by 17.24%, bringing Roivant... Full story

Yahoo Finance • 4 months ago

Immunovant drops 7%, prices $550M stock offering

* Clinical-stage immunology company Immunovant (IMVT [https://seekingalpha.com/symbol/IMVT]) priced [https://seekingalpha.com/pr/20336158-immunovant-announces-pricing-of-550-million-common-stock-financing] an underwritten offering of its... Full story

Yahoo Finance • 4 months ago

Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings

Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now. Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on Immunovant, Inc. (NASDAQ:IMVT)... Full story

Yahoo Finance • 5 months ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. B... Full story

Yahoo Finance • 5 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Immunovant Inc. Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing with potentially regi... Full story

Yahoo Finance • 5 months ago

Immunovant Q2 2026 Earnings Preview

* Immunovant (IMVT [https://seekingalpha.com/symbol/IMVT]) is scheduled to announce Q2 earnings results on Friday, November 7th, after market close. * The consensus EPS Estimate is -$0.73 [https://seekingalpha.com/symbol/IMVT/earnings/... Full story

Yahoo Finance • 5 months ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, Nov... Full story

Yahoo Finance • 6 months ago

Top Buys by Directors: Manheimer's $100.4K Bet on NTST

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earne... Full story

Yahoo Finance • 7 months ago

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s o... Full story

Yahoo Finance • 7 months ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3... Full story